TY - JOUR
T1 - Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer
AU - Altimari, Annalisa
AU - Grigioni, Antonia D Errico
AU - Benedettini, Elisa
AU - Gabusi, Elena
AU - Schiavina, Riccardo
AU - Martinelli, Antonio
AU - Morselli-Labate, Antonio Maria
AU - Martorana, Giuseppe
AU - Grigioni, Walter Franco
AU - Fiorentino, Michelangelo
PY - 2008/5
Y1 - 2008/5
N2 - To analyze the potential diagnostic relevance of free plasma DNA (FPDNA), we enrolled 64 patients with localized prostate cancer (CaP). FPDNA was quantified by real-time polymerase chain reaction assessment of the HTERT gene in blood samples from 64 patients with CaP and 45 healthy males. Methylation of the GSTP1 gene was used to confirm the neoplastic origin of FPDNA in selected cases. The mean ± SD levels of FPDNA were higher in patients with CaP (15.4 ± 10.9 ng/mL) than in control subjects (5.5 ± 3.5 ng/mL; P <.001). By using the best cutoff value, the sensitivity of the test was 80%, the specificity was 82%, the area under the receiver operating characteristic curve, 0.881. High FPDNA values were significantly associated with pathologic T3 stage (P = .035). Methylation of the GSTP1 gene was found in 4 (25%) of 16 FPDNA samples and 15 (94%) of 16 tissue samples. Quantification of FPDNA discriminates between patients with CaP and healthy subjects and correlates with pathologic tumor stage. FPDNA is a candidate biomarker for early diagnosis and monitoring of CaP.
AB - To analyze the potential diagnostic relevance of free plasma DNA (FPDNA), we enrolled 64 patients with localized prostate cancer (CaP). FPDNA was quantified by real-time polymerase chain reaction assessment of the HTERT gene in blood samples from 64 patients with CaP and 45 healthy males. Methylation of the GSTP1 gene was used to confirm the neoplastic origin of FPDNA in selected cases. The mean ± SD levels of FPDNA were higher in patients with CaP (15.4 ± 10.9 ng/mL) than in control subjects (5.5 ± 3.5 ng/mL; P <.001). By using the best cutoff value, the sensitivity of the test was 80%, the specificity was 82%, the area under the receiver operating characteristic curve, 0.881. High FPDNA values were significantly associated with pathologic T3 stage (P = .035). Methylation of the GSTP1 gene was found in 4 (25%) of 16 FPDNA samples and 15 (94%) of 16 tissue samples. Quantification of FPDNA discriminates between patients with CaP and healthy subjects and correlates with pathologic tumor stage. FPDNA is a candidate biomarker for early diagnosis and monitoring of CaP.
KW - Blood tumor markers
KW - DNA methylation
KW - Free plasma DNA
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=44849097875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44849097875&partnerID=8YFLogxK
U2 - 10.1309/DBPX1MFNDDJBW1FL
DO - 10.1309/DBPX1MFNDDJBW1FL
M3 - Article
C2 - 18426736
AN - SCOPUS:44849097875
VL - 129
SP - 756
EP - 762
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
SN - 0002-9173
IS - 5
ER -